C12N 2320/35
Based on a specific dosage / administration regimen
Official title: based on a specific dosage / administration regimen
C12N2320/35 (Based on a specific dosage / administration regimen) appears on 165 US grants and 359 published applications in this corpus.
Search patents in C12N- Granted patents
- 165
- Published applications
- 359
- Assignees
- 135
- Inventors
- 605
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 0 | 4 |
| 2009 | 0 | 8 |
| 2010 | 0 | 3 |
| 2011 | 2 | 3 |
| 2012 | 5 | 12 |
| 2013 | 4 | 4 |
| 2014 | 5 | 11 |
| 2015 | 6 | 10 |
| 2016 | 10 | 23 |
| 2017 | 12 | 30 |
| 2018 | 15 | 16 |
| 2019 | 14 | 24 |
| 2020 | 12 | 29 |
| 2021 | 11 | 36 |
| 2022 | 15 | 31 |
| 2023 | 12 | 29 |
| 2024 | 17 | 34 |
| 2025 | 12 | 25 |
| 2026 | 13 | 25 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for treatment of hepatitis D virus infection15 Sep 2026US 12,735,699 B2GlaxoSmithKline Intellectual Property (No. 3) Limited
- Dosing for treatment with anti-CD20/anti-CD3 bispecific antibody8 Sep 2026US 12,729,243 B2Hoffmann-La Roche Inc.
- Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression1 Sep 2026US 12,723,247 B2Alnylam Pharmaceuticals, Inc.
- Methods and compositions for treating glycogen storage diseases28 Jul 2026US 12,692,512 B2Ultragenyx Pharmaceutical Inc.
- Methods and compositions for rejuvenating CNS glial populations by suppresion of transcription factors21 Jul 2026US 12,686,868 B2University of Rochester
- Modulating apolipoprotein (a) expression8 Oct 2026US 2026/0308584 A1Ionis Pharmaceuticals, Inc.
- Antisense oligomer formulations8 Oct 2026US 2026/0308595 A1Stoke Therapeutics, Inc.
- Pcsk9 irna compositions and methods of use thereof1 Oct 2026US 2026/0297586 A1Alnylam Pharmaceuticals, Inc.
- Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof17 Sep 2026US 2026/0273070 A1City of Hope
- Prekallikrein-modulating compositions and methods of use thereof17 Sep 2026US 2026/0275354 A1ADARx Pharmaceuticals, Inc.
Most cited
By later US patents
- Oligomers139US 8,324,371 B2Royal Holloway and Bedford New College, University of London · 2012
- Oligomers125US 8,084,601 B2Royal Holloway and Bedford New College Royal Holloway, University of London · 2011
- Oligomers73US 8,461,325 B2Royal Holloway, University of London · 2013
- Oligomers43US 8,552,172 B22013
- Selective reduction of allelic variants40US 8,957,040 B2Isis Pharmaceuticals, Inc. · 2015